Bullish Case: Q3 beat with raised FY26 guide ($7.49-7.51B rev, $6.18-6.21 EPS), 7% core growth, FDA companion-diagnostic wins, and Biocare integration support momentum. Call volume leads puts by 81%, term structure is in contango with near-IV ~31% (cheap carry), and Helium's density peaks near $150-155 with market density peaking $150-160—post-earnings re-rating toward $170-175 has room given $161.94 spot and call-heavy flow at 165-175 strikes.

Bearish Case: At 7.9x book after a 23% 90-day rally, valuation is stretched and recent price action is flat—momentum is pausing. Helium's AI forecast is -2.07% with only 0.1 historical correlation, downside skew persists (Dec 120-140P at 36-43% IV vs. ATM ~31%), and the Helium density places meaningful mass below $140. UBS's neutral call on valuation and mean-reversion risk after +7.8% weekly gains argue for digestion, not extension.

Potential Outcomes:

1. 40% Consolidation $150-165: post-earnings digestion, contango IV persists, drift sideways into November.
2. 25% Bull continuation to $170-180: call flow (165C/180C leads) and raised guide sustain re-rating; falsified if $155 breaks.
3. 20% Pullback to $140-150: valuation + skew resolves; put IV already prices this tail.
4. 10% Sharp correction <$140: macro rotation or guidance miss at Q4 (early Dec report).
5. 5% M&A/strategic surprise >$185: low-probability given size.

September 22, 2026